Fluconazole interferes with the cytochrome P-450-dependent enzyme C-14a-demethylase, which is responsible for production of ergosterol, the major component of the fungal cell membrane. The disruption of ergosterol synthesis causes structural and functional changes in the membrane which predispose the fungus to osmotic and immune-mediated damage and interfere with cell adherence, The triazole derivatives bind to the cytochrome P-450 enzyme with greater specificity than their predecessors. Additional antifungal activity may be accounted for by the azole inhibition of cytochrome c oxidative and peroxidative enzymes, leading to increased intracellular peroxidase. Caution must be exercised in the administration of fluconazole to patients with impaired renal func-
in the same family as ketoconazole and itraconazole. Fluconazole has several advantages over the other antifungal drugs including the option of oral therapy. The side-effect profile is minimal. Studies have shown it to be efficacious for the treament of vaginal yeast infections in a single oral dose.
STRUCTURE AND DERIVATION
Fluconazole [(difluoro-2,4-phenyl)-2-bis((1H-triazole-l,2)-4-yl-1)-l,3-propanol-2] is an azole antifungal agent. The imidazole, i.e., ketoconazole, has been modified by the replacement of the imidazole ring with a triazole ring, addition of a second triazole ring, and substitution of a difluorophenyl moiety for a dichlorophenyl moiety. These changes provide more selective inhibition of fungal enzyme systems, greater metabolic stability, and enhanced water solubility.
MECHANISM OF ACTION
Fluconazole interferes with the cytochrome P-450-dependent enzyme C-14a-demethylase, which is responsible for production of ergosterol, the major component of the fungal cell membrane. The disruption of ergosterol synthesis causes structural and functional changes in the membrane which predispose the fungus to osmotic and immune-mediated damage and interfere with cell adherence, The triazole derivatives bind to the cytochrome P-450 enzyme with greater specificity than their predecessors. Additional antifungal activity may be accounted for by the azole inhibition of cytochrome c oxidative and peroxidative enzymes, leading to increased intracellular peroxidase. 15 In patients with normal renal function, the half-life is 31 h. This half-life is increased to 98 h in patients with creatinine clearances of <20 ml/min. The manufacturer, therefore, recommends a decreased dose in patients with renal insufficiency.
SIDE EFFECTS AND INTERACTIONS
The side-effect profile of fluconazole is favorable. Only 8.9% of the patients treated with a single 150-mg oral dose experienced adverse effects considered to be "possibly related" or "definitely related" to the drug. 16 The most common complaint was nausea (3.3%), followed by headache (1.2%), abdominal pain (0.8%), dizziness (0.7%), and heartburn or indigestion (0.7%). The COST Table presents the retail costs to the patient. These costs will vary depending on the geographic location.
SUMMARY
The modified structure of fluconazole gives it several advantages over its predecessors, including excellent oral bioavailability and an improved sideeffect profile. In a single oral dose of 150 mg, fluconazole is efficacious against candidal vaginitis.
